Please login to the form below

Not currently logged in
Email:
Password:

Momenta

This page shows the latest Momenta news and features for those working in and with pharma, biotech and healthcare.

Merck confirms sale of biosimilar division

Merck confirms sale of biosimilar division

All told, more than a dozen companies, including Amgen, Samsung Bioepis, Boehringer Ingelheim, Momenta Pharmaceuticals and Sandoz, are developing Humira biosimilars, which may be a factor behind Merck's decision to

Latest news

  • Shire gives up on Momenta-partnered Humira biosimilar Shire gives up on Momenta-partnered Humira biosimilar

    Shire has called time on collaboration with Momenta Pharmaceuticals on the development of a biosimilar version of AbbVie's Humira. ... Momenta said Shire took the decision after a "comprehensive portfolio assessment" that followed its $32bn acquisition

  • Mylan buys into six biosimilars, including Orencia candidate Mylan buys into six biosimilars, including Orencia candidate

    Mylan buys into six biosimilars, including Orencia candidate. Deal with Momenta bolsters biosimilars pipeline for new products. ... Generic pharmaceutical giant Mylan has boosted its position in the emerging biosimilar market via a $245m agreement with

  • Another setback for Teva's laquinimod in MS Another setback for Teva's laquinimod in MS

    but is now facing generic competition in the US from Sandoz/Momenta's Glatopa.

  • Pfizer links with Synthon on generic Copaxone Pfizer links with Synthon on generic Copaxone

    Copaxone (glatiramer acetate) already has one rival in the US market in the form of Sandoz and Momenta's Glatopa, and Pfizer will also try to grab a slice of the

  • Generic Copaxone launches in US Generic Copaxone launches in US

    Generic Copaxone launches in US. Sandoz and Momenta Pharmaceuticals started shipping Glatopa in reaction. ... Immediately, Novartis' Sandoz generics division and partner Momenta Pharmaceuticals started to ship their Glatopa brand of 20mg glatiramer

More from news
Approximately 3 fully matching, plus 15 partially matching documents found.

Latest Intelligence

  • Building a bright future Building a bright future

    Mylan’s biosimilar of the multiple sclerosis injection therapy copaxane is not gliding to the promised land, and delays have given rivals Momenta and Novartis’Sandoz a tilt at the

  • Deal Watch January 2017 Deal Watch January 2017

    625. Momenta. CSL. Licence. M230 immuno-modulator of Fc receptors. 600. ImmuNext.

  • Deal Watch January 2016 Deal Watch January 2016

    255. Mylan/ Momenta. Co-development, co-commercialisation . Exclusive global collaboration with Momenta for 6 biosimilars including a biosimilar version of Orencia (abatacept).

  • Modern anticoagulants threaten status quo Modern anticoagulants threaten status quo

    The LMWH pipeline includes three compounds: certoparin sodium (Embolex; Novartis), semuloparin (Visamerin; Sanofi) and adomiparin (Momenta Pharmaceuticals).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Quintiles

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

the_other_side_of_rheumation_arthritis_thumb.jpg
THE OTHER SIDE OF … RHEUMATOID ARTHRITIS
“I harassed my GP enough to get it caught early”...
The big dilemma in international digital pharma marketing
How to get consistent international marketing while meeting local affiliates’ needs....
Why pharma content marketing campaigns should be agile
Agile pharma content marketing is simply about responding to customer needs, rather than your own whims....

Infographics